(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 7.05% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Cytek Biosciences's revenue in 2026 is $201,493,000.On average, 7 Wall Street analysts forecast CTKB's revenue for 2026 to be $27,306,619,889, with the lowest CTKB revenue forecast at $26,177,949,695, and the highest CTKB revenue forecast at $28,183,331,817. On average, 7 Wall Street analysts forecast CTKB's revenue for 2027 to be $29,225,873,420, with the lowest CTKB revenue forecast at $27,048,234,116, and the highest CTKB revenue forecast at $30,439,386,703.
In 2028, CTKB is forecast to generate $31,925,426,276 in revenue, with the lowest revenue forecast at $29,605,096,321 and the highest revenue forecast at $33,429,462,867.